Sarepta prepares to present new data on Duchenne and limb-girdle muscular dystrophy gene therapy programs this week.

Shares of Sarepta Therapeutics rose nearly 5% in early premarket trading on Wednesday as the company prepared to present new ...

After three patients died, the maker of an investigational gene therapy stopped shipments of the drug after it refused to ...

Three patient deaths linked to neuromuscular drugs developed by Sarepta Therapeutics (NASDAQ:SRPT) have drawn regulatory scrutiny on the viral vector used in the company’s gene therapy platform ...

WASHINGTON (AP) — Shares of beleaguered drugmaker Sarepta Therapeutics jumped in afterhours trading Monday after the company said it would resume shipping its gene therapy for some patients, following ...

Sarepta Therapeutics faces major risks in 2025 with stock collapse, halted therapies, and financial woes. Click here to read ...

CHMP issued a negative opinion on Elevidys for Duchenne patients aged 3–7 despite secondary gains in motor function. Elevidys has treated over 900 DMD patients, but EMA and FDA raise concerns over ...